Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects

Pediatric Drugs

Volumn 14, Issue 2, 2012, Pages 119-130

  Comstock, Timothy L ^a   Paterno, Michael R ^a   Bateman, Kirk M ^a   DeCory, Heleen H ^a   Gearinger, Matthew ^b  

^a BAUSCH AND LOMB   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Blepharoconjunctivitis; Chalazion; Children; Conjunctivitis; Eye disorders; Intraocular pressure; Loteprednol etabonate; Loteprednol etabonatetobramycin; Ophthalmic; Tobramycin; Tobramycindexamethasone; Visual acuity.

Indexed keywords

DEXAMETHASONE PLUS TOBRAMYCIN; EYE DROPS; LOTEPREDNOL ETABONATE; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN; PLACEBO; TOBRAMYCIN;

ACUTE OTITIS MEDIA; ARTICLE; BRONCHIOLITIS; CHALAZION; CHICKENPOX; CHILD; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA DISEASE; COUGHING; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; EYE DISCHARGE; EYE INFLAMMATION; EYE PAIN; EYELID DISEASE; EYELID ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HORDEOLUM; HUMAN; INFANT; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; OTITIS MEDIA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RHINITIS; RHINOPHARYNGITIS; SEBACEOUS GLAND DISEASE; SORE THROAT; STATISTICAL SIGNIFICANCE; SUBDURAL HEMATOMA; SUSPENSION; TONOMETRY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VOMITING;

ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; EYELIDS; FEMALE; FEVER; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFLAMMATION; INTRAOCULAR PRESSURE; MALE; MULTICENTER STUDIES AS TOPIC; OPHTHALMIC SOLUTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY; TOBRAMYCIN; VISION, OCULAR; VISUAL ACUITY;

EID: 84857302654     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11596320-000000000-00000     Document Type: Article

References (40)

1. Sendrowski DP, Jaanus SD, Semes LP, et al. Anti-inflammatory drugs. In: Bartlett JD, Jaanus SD, editors. Clinical ocular pharmacology. 5th ed. Boston (MA): Butterworth-Heinemann, 2008: 221-61
2. Duggan RK. Certain steroid preparations for ophthalmic and/or otic use. Drugs for human use: drug efficacy study implementation. Washington, DC: US Food and Drug Administration Fed Regist, 1971; 36: 20151-3
3. Armaly MF. Effects of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963; 70: 482-91
4. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963; 70: 500-7
5. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965; 4: 198-205
6. Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993; 9: 157-65 (Pubitemid 23187584)
7. Jones III R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17: 163-7 (Pubitemid 43790812)
8. Urban Jr RC, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986; 31: 102-10 (Pubitemid 17173020)
9. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11: 478-83
10. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002; 25: 33-55 (Pubitemid 34208330)
11. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992; 9: 1275-8
12. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991; 10: 933-7
13. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997; 123: 455-64 (Pubitemid 27171850)
14. Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-Operative Inflammation Study Group 1. J Cataract Refract Surg 1998; 24: 1480-9 (Pubitemid 28509816)
15. Loteprednol Etabonate Postoperative Inflammation Study Group 2.Adoublemasked, placebo-controlled evaluation of 0.5% loteprednol etabonate for postoperative inflammation. Ophthalmology 1998; 105: 1780-6
16. Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 2009; 28: 1139-43
17. Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during long-term use of loteprednol etabonate. Glaucoma 1998; 7: 266-9 (Pubitemid 29149820)
18. Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999; 127: 537-44
19. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984; 74: 1803-10 (Pubitemid 15214094)
20. Zylet- (loteprednol etabonate and tobramycin) eye drops: package insert. Tampa (FL): Bausch & Lomb Incorporated, 2010 May
21. Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008; 27: 50-5
22. Bartlett JD, Holland EJ, Usner DW, et al. Tolerability of loteprednol/ tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study. Curr Med Res Opin 2008; 24: 2219-27
23. White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008; 24: 287-96 (Pubitemid 351181204)
24. Bausch & Lomb, Inc. Pediatric Zylet safety and efficacy study [Clinical- Trials.gov identifier NCT00420628]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Dec 29].
25. Bausch & Lomb, Inc. Safety and efficacy of Zylet vs lotemax, tobramycin and vehicle in pediatric blepharoconjunctivitis [ClinicalTrials.gov identifier NCT00705159]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Dec 29].
26. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997; 23: 31-6 (Pubitemid 27043763)
27. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993; 12: 313-21 (Pubitemid 23162150)
28. Dell SJ, Shulman DG, Lowry GM, et al.A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997; 123: 791-7 (Pubitemid 27250926)
29. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998; 102: 251-5
30. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2%in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004; 30: 10-3 (Pubitemid 43196972)
31. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999; 106: 362-9 (Pubitemid 30191638)
32. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patientswith delayed tear clearance.AmJOphthlamol 2004; 138: 444-57 (Pubitemid 39208573)
33. Comstock TL, Holland EJ. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opin Pharmacother 2010; 11: 843-52
34. Fan DS, Ng JS, Lam DS. A prospective study on ocular hypertensive and antiinflammatory response to different dosages of fluorometholone in children. Ophthalmology 2001; 108: 1973-7 (Pubitemid 33032763)
35. Ng JS, Fan DS, Young AL, et al. Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology 2000; 107: 2097-100
36. Lee YJ, Park CY, Woo KI. Ocular hypertensive response to topical dexamethasone ointment in children. Korean J Ophthalmol 2006; 20: 166-70
37. Ohji M, Kinoshita S, Ohmi E, et al. Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol 1991; 112: 450-4
38. Kwok AK, Lam DS, Ng JS, et al. Ocular hypertensive response to topical steroids in children. Ophthalmology 1997; 104: 2112-6 (Pubitemid 28053439)
39. Fan DS, Yu CB, Chiu TY, et al. Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children.ArchOphthalmol 2003; 121: 1716-21 (Pubitemid 37517438)
40. Jones SM, Weinstein JM, Cumberland P, et al. Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology 2007; 114: 2271-80 (Pubitemid 350181090)